Mandate

VINGE ADVISES WILLIS IN ACQUISITION OF MAX MATTHIESSEN

June 13, 2014

Vinge assists global risk adviser, insurance and reinsurance broker Willis Group Holdings plc in connection with its acquisition of a controlling stake in Max Matthiessen. Willis acquires approximately 75 % of the Swedish employee benefits advisor for approximately SEK 1.357 billion from Altor Fund III (50 %) and employees (25 %). Approximately 25 % is retained by employees.
 
Willis is listed on NYSE and operates on every continent with more than 18,000 employees in over 400 offices. Willis Sweden has 140 employees in four offices and is headquartered in Stockholm.
 
Max Matthiessen operates in retirement savings, health plans and personal insurance. The company has around 420 employees in 23 locations across Sweden. Gross turnover in 2013 exceeded SEK 1 billion. The combined business of Willis and Max Matthiessen will create the biggest risk adviser and broker in the Nordic region.
 
The acquisition is conditional upon customary regulatory approvals and conditions to closing.
 
Vinge’s team consisted of among others responsible partner Carl Gustaf De Geer, partner Malin Ohlin, project manager Peter Sundgren and associates Filip Brosset and Sofie Bjärtun (M&A), as well as associates Axel Hedberg (financial regulatory), Nina Farrahi (compliance), Emil Fahlén Godö (competition law) and Evelina Tejle (employment law).

 

Related

Vinge has advised Egetis Therapeutics in connection with a directed share issue

Vinge has advised Egetis Therapeutics AB (publ) (“Egetis Therapeutics”), listed on Nasdaq Stockholm, in connection with a directed share issue whereby Egetis Therapeutics raised proceeds of approximately SEK 183 million before transaction costs.
October 06, 2025

Vinge worked with funds advised by Agilitas on the buy-out of Vivicta (previously Tietoevry Tech Services), including on the issuance of senior secured bonds and on entering into a super senior RCF

Vinge, together with O’Melveny as lead counsel and Avance, worked with funds advised by Agilitas Private Equity LLP (“Agilitas”), the pan-European mid-market private equity firm, in their backing of Vivicta. The buy-out was previously announced on 24 March 2025 and closed on 2 September 2025.
October 03, 2025

Vinge has advised Hansa Biopharma in connection with a directed share issue of approx. SEK 671.5 million

Vinge has advised Hansa Biopharma AB (publ) in connection with a directed share issue through which the company raises proceeds of approx. SEK 671.5 million before transaction costs.
October 03, 2025